Zoono Group Limited · ASX:ZNO
Zoono — Shareholder Meeting (November 2019)
33 slides from Zoono's shareholder meeting presentation, Nov 7, 2019
Slide 1: Zoono Group Limited AGM Presentation
For personal use only Zoono Group Limited AGM Presentation Sydney November 2019 Paul Hyslop Managing Director/CEO
Slide 2: Revenues & Other Income & Profit Reported (NZD)
For personal use only Revenues & • $1.78 million Revenue & Other Other Income Income 12 months to 30 June 2019. & Profit • $2.45 million loss 12 months to Reported (NZD) 30 June 2019.
Slide 3: Balance Sheet Summary – 30 June 2019 (NZD)
Cash on hand: $3.1M For personal use only Total Assets: $4.7M Balance Total Liabilities: $0.8M Sheet (includes Deferred Income of Summary – $0.3M) Total Equity: $3.8M (82% of 30 June 2019 Total Assets) (NZD) NB: Please refer to 30 June 2019 Annual Report for further details
Slide 4: First Quarter Financial Highlights
First Quarter For personal use only Financial Highlights (NZD) • $1.2M in cash receipts. • $199,000 operating cash flow positive. • New Distributors signed. • Increased Cash at Bank. • Expect operating cash flow positive FY20.
Slide 5: October Update
For personal use only October Update (NZD) • Cash on Hand at 31 October 2019: $3.1M. • $300,000+ of orders received in October.
Slide 6: New Distributors Signed
New Distributors Signed For personal use only • Double Bond Pharma Sweden. • Denmark, Finland. • Bosnia & Herzegovina, Croatia, Serbia, Montenegro. • South Africa and adjoining Countries. • Iraq, Egypt, Syria. • Several new agreements under negotiation.
Slide 7: United Kingdom
United Kingdom For personal use only • UK operation set up in Bury St Edmonds, Suffolk and operating for over a year now – NZD$250,000 of sales since year-end. • Three staff including one sales rep and marketing manager for the UK and Europe. Further staff to be employed as business growth dictates.
Slide 8: Central Europe
Central Europe For personal use only • Distribution Agreement signed with Midas Pharma GmbH in Germany for sales and distribution in the EU and selected global markets; • Utilise Midas’ developed sales and distribution channels across the global pharmaceutical and healthcare sectors. • Sales since y
Slide 9: South Eastern Europe
South Eastern Europe For personal use only • TEH D.O.O. Distribution Agreement; • Bosnia-Herzegovina | Croatia | Serbia | Montenegro • First 12 months: NZD $0.4M • Second 12 months: NZD $0.5M • Third 12 months: NZD $0.6M • YOY 10% increase after year 3 • $133,000 NZD orders received to date since ye
Slide 10: Middle East
Middle East For personal use only • ASH Group FZE LLC Distribution Agreement • Egypt, Syria and Iraq; • First 12 months: NZD $0.4M • Second 12 months: NZD $0.5M • Third 12 months: NZD $0.8M • YOY 10% increase after year 3 • $110,000 NZD order pending since year-end.
Slide 11: Africa
Africa For personal use only • International Nutrition and Sport SA (Pty) Ltd Distribution Agreement; • South Africa, Botswana, Lesotho, Swaziland, Zambia and Namibia • First 12 months: NZD $0.7M • Second 12 months: NZD $0.8M • Third 12 months: NZD $1.0M • YOY 10% increase after year 3 • $201,000 NZ
Slide 12: China
China For personal use only • Permanent agent based in China. • Guangzhou Sanchengyun Trade Co; Online Zoono branded sales Distribution agreement; • First 12 months: NZD $0.9M • Second 12 months: NZD $1.2M • Third 12 months: NZD $1.6M • YOY 10% increase after year 3 • Deposit received of NZ$470,000
Slide 13: China
China For personal use only • Asizoono Intelligent Biotechnology (Guangzhou) sales Distribution agreement – Stomatology industry China • First 12 months: NZD $0.2M • Second 12 months: NZD $0.5M • Third 12 months: NZD $0.7M • YOY 10% increase after year 3 • Order received of NZ$55,000 to be delivered
Slide 14: New Zealand
New Zealand For personal use only • Distribution Agreement with Zoono Poultry (formerly The Z Factor) for the supply of its proprietary poultry formulation utilising Zoono Z-71 Microbe Shield for use in the poultry industry. Successful trials undertaken. • Sales into the pig and poultry industry sin
Slide 15: Australia
Australia For personal use only • Zoono Poultry are negotiated an agreement for national distribution in the Agri business, with a nation wide distributor. • Additional trials underway with leading industry brands. • Childcare and aged care major targets. • Online sales performing well.
Slide 16: USA
USA For personal use only • MicroSonic LLC Distribution Agreement to supply products to Turtle Wax Inc: • Calendar Year 2020: NZD $3.1 million • Calendar Year 2021: NZD $4.7 million • YOY increases thereafter • All registrations now in place and we expect the Turtle Wax business to commence shortly.
Slide 17: USA cont.
USA cont. For personal use only • Sales being made across several states into the Visiting Nurses Association. • Sales being made to the two major airports in Texas. • Sales being made into the Texas school districts. • Negotiations underway with aged care chain facilities. • CVS Pharmacy has also a
Slide 18: Marketing Activity
Marketing Activity For personal use only SOCIAL MEDIA, SAMPLING & NEW PRODUCT PAID SOCIAL/ INFLUENCER COLLABORATIONS DEVELOPMENT DIGITAL ADVERTISING MARKETING
Slide 19: Consumer Feedback
For personal use only Consumer Feedback
Slide 20: Positive Impact. Positive Sales.
For personal use only Positive Impact. Positive Sales. • Success creating a healthier environment for chickens. • Zoono is a substitute for dangerous chemicals and has the potential to reduce the need for antibiotics. • The results: • Chickens are healthier and consume less food (cost saving) • They
Slide 21: Reducing Risk of African Swine Flu Outbreaks
For personal use only Reducing Risk of African Swine Flu Outbreaks • African Swine Flu could kill up to 25% of the world’s pig population • Swine Flu is spread via contaminated objectives • Trails are scheduled with leading industry participants in China. • Positive results to date.
Slide 22: Current Focus
Current Focus For personal use only • Large Childcare/Aged Care Groups in Australia. • Poultry Trials Australia, China, Portugal. • Swine Trials Russia, China, Korea, Australia. • Rollout commenced Dorint Hotel Group Germany 60 hotels, average hotel 300-400 rooms. Monthly fogging treatment rooms and
Slide 23: Current Focus Cont.
Current Focus Cont. For personal use only • India – expect orders soon as regulatory approvals and trials are completed. Healthcare, education and corporate sectors. • USA – Aged care and Education. • USA – Cruise and Airline Industry • USA – Microsonic/Turtle Wax.
Slide 24: China Agri
For personal use only CHINA AGRI
Slide 25: China Agri – Before and After
CHINA AGRI For personal use only BEFORE AND AFTER 8999 TO 109
Slide 26: China Agri – Before and After
CHINA AGRI For personal use only BEFORE AND AFTER 7879 TO 36
Slide 27: China Agri
For personal use only CHINA AGRI
Slide 28: China Agri
For personal use only CHINA AGRI
Slide 29: China Aquaculture
For personal use only CHINA AQUACULTURE
Slide 30: Strategy B2B
Strategy B2B For personal use only • B2B business, targeting Facilities Management, cleaning companies, end user companies like Hotels Hospitality, Childcare, Aged Care specific industry distribution companies. • Animal Science, in particular Pig and Poultry big target industries, product being test
Slide 31: Strategy B2C
For personal use only Strategy B2C • B2C main target is online sales where we maximise GP margin, including Amazon and own websites. • Should volumes dictate we will look at B2C white label deals but with minimum annual orders of NZD$1m
Slide 32: Key Market/Customers
Key Market/Customers For personal use only • EU.UK / MIDAS/ Double Bond/ Large Pharma/ Zoono Pig Poultry/ Germany - Hotels FM Companies/ Hospitality/ Healthcare. • USA / Microsonic/ Turtle Wax/ School Districts/ Aged Care/ CVS/ FM companies/ Cruise and Airline. • China / Online Sales/ Healthcare/ Ch
Slide 33: Thank you
For personal use only Thank you